Obu Health review

Obu Health makes the disclosure that matters most: it names both compounding pharmacies it works with — Manifest Pharmacy in Greer, South Carolina and RX Compounding Store in Miami, Florida — alongside a named LLC, a street address and a named doctor network, MD Integrations. Its sermorelin is $149 a month with the provider visit, dose adjustments and expedited shipping stated as included, and its NAD⁺ injection is $219 a month on the same terms. The thing to read before ordering is the returns policy: all medication sales are final.

OBU Health LLC is a Las Vegas telehealth platform at 10845 Griffith Peak Dr, running a compact four-product catalog: sermorelin from $149, NAD+ Injection at $219, compounded semaglutide from $190/mo and compounded tirzepatide from $239/mo. It advertises US board-certified physician review within about 24 hours, free expedited shipping, discreet packaging and a stated four-test pharmacy quality panel, and its footer shows a 'LegitScript Certified' seal image.

Asynchronous and questionnaire-based: a short health assessment, licensed physician review, and delivery from one of two named partner pharmacies. Two features stand out. The first is supply-chain transparency — naming Manifest Pharmacy and RX Compounding Store matters, because it means you can look up who prepares your medication rather than accepting 'a licensed US pharmacy' as an answer. The second is that its product pages state what the price covers: the provider consultation, ongoing care and dose adjustments are all listed as included, with free expedited shipping and pause-or-cancel-anytime terms, and its sermorelin plan explicitly promises the same price per vial on the monthly plan and the same price at every refill on the three-month plan. The gaps: no medical director is named publicly, though the FAQ names its provider network, MD Integrations, and the physicians assigned to patients in California, Massachusetts, Rhode Island and Vermont; no enumerated state list exists (the FAQ says the US only, with restrictions depending on therapy and state, disclosed at intake); some states require a live chat or video consultation rather than the questionnaire alone; and the refund position is firm — federal and state law do not allow medication returns, so all sales are final. Subscription auto-renewal mechanics are only lightly documented, so read them at checkout.

Sermorelin is $149 per month on the monthly plan or $379 for three months, and the NAD⁺ injection is $219 per month, each with the provider visit, dose adjustments, ongoing care and free expedited shipping stated as included. The sermorelin plan cards add two useful promises: the same price per vial on the monthly plan and the same price at every refill on the three-month plan. Obu's own comparison table puts its prices against several named competitors, which is marketing framing rather than our assessment. On the GLP-1 side the tiers are shown in full — compounded semaglutide at $190 monthly, $399 for three months and $714 for six, compounded tirzepatide from $239 a month — and the semaglutide page states the same price at every dose. The sermorelin and NAD⁺ pages make no equivalent dose statement, so confirm at intake that $149 and $219 hold if your dose rises. None of the GLP-1 figures is a peptide or NAD⁺ price.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Obu states this in its own FAQ — compounded sermorelin is not FDA-approved, is prepared by a US-licensed pharmacy under Section 503A, and is dispensed only against a patient-specific prescription, with the FDA not reviewing or approving compounded medications for safety, effectiveness or quality. That is an unusually precise disclosure, and it is backed by naming the two pharmacies. Compounded sterile preparations are still not reviewed by the FDA for purity and potency the way approved drugs are. On evidence, sermorelin is a GHRH analog that signals your own pituitary to release growth hormone rather than replacing it, which preserves the natural feedback loop — a real, well-described mechanism whose long-term human outcome data behind sleep, recovery and body-composition claims stays thin. Obu's own FAQ makes the sermorelin-versus-HGH distinction correctly. Injected NAD⁺ is weaker: no controlled human outcome trials exist for it, and the NAD⁺ forms with human data are the oral precursors NR and NMN, which raise blood NAD⁺ — a biomarker, not a clinical outcome. Individual results vary.